Bivin & Associates’s Chemours CC Stock Holding History

Bivin & Associates’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6	Closed	–	–	327
2022 Q1	$0	Hold	6	–	–	﹤0.01%	358
2021 Q4	$0	Buy	+6	New	+$187	﹤0.01%	398

Other funds holding CC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bivin & Associates's CC Position: Q2 2022 in Review

Bivin & Associates sold out of Chemours (CC) in Q2 2022, closing a stake of 6 shares.

Bivin & Associates first reported a position in CC in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 517 funds tracked by Wall St. Rank hold CC as of Q2 2022.

Bivin & Associates reported no remaining Chemours position as of Q2 2022 after selling out during the quarter.
Bivin & Associates sold 6 Chemours shares in Q2 2022.
Bivin & Associates first reported a position in Chemours in Q4 2021 and held it in 2 quarters.
Bivin & Associates's Chemours position peaked at $0 in Q1 2022.
517 funds tracked by Wall St. Rank held Chemours as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.